Convergence Pharmaceuticals
CAMBRIDGE, England, July 19, 2011 -
Convergence Pharmaceuticals Limited ("Convergence"), the company
focused on the development of novel and high value analgesic
medicines, today announces that the Phase II proof of concept study
with CNV1014802 for treating pain associated with lumbosacral
radiculopathy (LSR) has started.
CAMBRIDGE, England, April 21, 2011 - Convergence Pharmaceuticals Limited ("Convergence"), the company focused
on the development of novel and high value analgesic medicines, today
announced that the first-time-in-man Phase I study of the novel, first in
class calcium channel blocker CNV2197944, for the treatment of chronic pain
has been initiated and dosing has begun.
